keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer recurrence

keyword
https://www.readbyqxmd.com/read/28816169/long-term-results-of-a-randomized-trial-comparing-iridium-implant-plus-external-beam-radiation-therapy-with-external-beam-radiation-therapy-alone-in-node-negative-locally-advanced-cancer-of-the-prostate
#1
Ian S Dayes, Sameer Parpia, Jaclyn Gilbert, Jim A Julian, Ian R Davis, Mark N Levine, Jinka Sathya
PURPOSE: To determine the impact on long-term survival from the addition of brachytherapy to external beam radiation therapy (EBRT) in patients with prostate cancer. METHODS AND MATERIALS: Between 1992 and 1997, 104 men with cT2-3, surgically staged node-negative prostate cancer were randomized to receive either EBRT (40 Gy/20 fractions) with iridium implant (35 Gy/48 hours) or EBRT alone (66 Gy/33 fractions) to the prostate. According to T stage, Gleason score, and prostate-specific antigen level, 60% of patients had high-risk disease...
September 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28816074/prostate-specific-antigen-after-salvage-radiotherapy-for-postprostatectomy-biochemical-recurrence-predicts-long-term-outcome-including-overall-survival
#2
Detlef Bartkowiak, Reinhard Thamm, Dirk Bottke, Alessandra Siegmann, Dirk Böhmer, Volker Budach, Thomas Wiegel
BACKGROUND: For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) is a second chance of cure. However, depending on risk factors, 40-70% of the patients experience further progression. With a focus on the pre- and post-SRT serum level of the prostate-specific antigen (PSA), we assessed the determinants of the long-term outcome after SRT. PATIENT AND METHODS: Between 1997 and 2011, 464 patients received 3D-conformal SRT with median 66...
August 17, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28815979/is-choline-based-pet-imaging-still-relevant-in-recurrent-prostate-cancer
#3
EDITORIAL
Nathan Lawrentschuk, Julia M Corfield, Andrew Scott
No abstract text is available yet for this article.
September 2017: BJU International
https://www.readbyqxmd.com/read/28814879/circulating-tumor-cells-correlate-with-patterns-of-recurrence-in-patients-with-hormone-sensitive-prostate-cancer
#4
Giandomenico Roviello, Silvia Paola Corona, Alberto Bonetta, Maria Rosa Cappelletti, Daniele Generali
The aim of this study was to evaluate the correlation between circulating tumor cells (CTCs) and patterns of recurrence in patients with hormone-sensitive prostate cancer. The study involved patients with histologically confirmed, advanced prostatic adenocarcinoma, who were tested for CTCs (Veridex(®)) when they developed recurrence after radical prostatectomy or external beam radiation between 2008 and 2014. Forty-two prostate cancer patients were evaluated. CTCs were detected in 14 out of 42 (33.3%) patients (Group A), while the remaining 28 (66...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28814451/androgen-deprivation-and-immunotherapy-for-the-treatment-of-prostate-cancer
#5
Melissa Gamat, Douglas G McNeel
Prostate cancer is the most common newly diagnosed malignancy in men, and the second most common cause of cancer-related death in the United States. The primary treatment for recurrent prostate cancer is androgen deprivation, and this therapy is typically continued life-long for patients with metastatic prostate cancer. Androgens and androgen deprivation have profound effects on the immune system, a finding that has become more appreciated in an era where immune-based treatments for cancer are being increasingly explored...
August 16, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28813230/dietary-supplements-commonly-used-by-cancer-survivors-are-there-any-benefits
#6
Mary J Marian
Following a cancer diagnosis, dietary supplements are reportedly used by 20%-80% of individuals. Supplements are most commonly used by breast cancer survivors, followed by patients with prostate, colorectal, and lung cancers, which is not surprising since these are the most common types of cancer diagnosed in adults. Reasons cited for such use include improving quality of life, reducing symptoms related to treatment and/or the disease process, and recommendation from medical practitioners; family and friends may also be an influence...
August 1, 2017: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/28807747/pretreatment-3t-multiparametric-mri-staging-predicts-for-biochemical-failure-in-high-risk-prostate-cancer-treated-with-combination-high-dose-rate-brachytherapy-and-external-beam-radiotherapy
#7
John V Hegde, D Jeffrey Demanes, Darlene Veruttipong, Jagdeep Raince, Sang-June Park, Steven S Raman, Nicholas G Nickols, Christopher R King, Amar U Kishan, Michael L Steinberg, Mitchell Kamrava
PURPOSE: To determine whether pretreatment 3T multiparametric MRI (mpMRI) staging impacts biochemical recurrence-free survival (BRFS) or distant metastasis-free survival (DMFS) for men with high-risk prostate cancer treated with combination high-dose-rate (HDR) brachytherapy and external beam radiation therapy (EBRT). MATERIALS AND METHODS: This institutional review board-approved retrospective study included a cohort of 37 men with high-risk prostate cancer treated with HDR brachytherapy and EBRT after 3T mpMRI...
August 11, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28807532/multicenter-evaluation-of-biochemical-relapse-free-survival-outcomes-for-intraoperatively-planned-prostate-brachytherapy-using-an-automated-delivery-system
#8
Kevin Martell, Siraj Husain, Daniel Taussky, Steve Angyalfi, Guila Delouya, Philippe Després, Luc Beaulieu, Andre-Guy Martin, Eric Vigneault
PURPOSE: To report biochemical recurrence in prostate cancer treated with intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB). METHODS AND MATERIALS: Between 2003 and 2013, 2608 patients from 3 centers were treated with IO-LDRB as single-modality treatment for low or low-tier intermediate-risk prostate cancer. Databases from the 3 centers have been analyzed. These independent databases were collected prospectively...
June 6, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28806256/recurrent-malignant-melanoma-detected-on-18f-fluciclovine-pet-ct-imaging-for-prostate-cancer
#9
Eugene J Teoh, Maria T Tsakok, Kevin M Bradley, Katherine Hyde, Manil Subesinghe, Fergus V Gleeson
A 66-year-old man presented with biochemical recurrence of prostate cancer and underwent F-fluciclovine PET/CT to detect sites of recurrence. He had a history of resected truncal stage IIIC malignant melanoma, with bilateral axillary node involvement on sentinel node biopsy, in complete remission for 3 years. F-fluciclovine PET/CT demonstrated an incidental fluciclovine-avid right axillary node (SUVmax = 4.3). Diagnostic sampling confirmed recurrent malignant melanoma.
August 12, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28805821/opposing-effects-of-cancer-type-specific-spop-mutants-on-bet-protein-degradation-and-sensitivity-to-bet-inhibitors
#10
Hana Janouskova, Geniver El Tekle, Elisa Bellini, Namrata D Udeshi, Anna Rinaldi, Anna Ulbricht, Tiziano Bernasocchi, Gianluca Civenni, Marco Losa, Tanya Svinkina, Craig M Bielski, Gregory V Kryukov, Luciano Cascione, Sara Napoli, Radoslav I Enchev, David G Mutch, Michael E Carney, Andrew Berchuck, Boris J N Winterhoff, Russell R Broaddus, Peter Schraml, Holger Moch, Francesco Bertoni, Carlo V Catapano, Matthias Peter, Steven A Carr, Levi A Garraway, Peter J Wild, Jean-Philippe P Theurillat
It is generally assumed that recurrent mutations within a given cancer driver gene elicit similar drug responses. Cancer genome studies have identified recurrent but divergent missense mutations affecting the substrate-recognition domain of the ubiquitin ligase adaptor SPOP in endometrial and prostate cancers. The therapeutic implications of these mutations remain incompletely understood. Here we analyzed changes in the ubiquitin landscape induced by endometrial cancer-associated SPOP mutations and identified BRD2, BRD3 and BRD4 proteins (BETs) as SPOP-CUL3 substrates that are preferentially degraded by endometrial cancer-associated SPOP mutants...
August 14, 2017: Nature Medicine
https://www.readbyqxmd.com/read/28805047/outcomes-of-post-prostatectomy-radiotherapy-at-a-regional-cancer-centre
#11
Luke Nicholls, Amber Winter, Ashley Harwood, Ashley Plank, Preeti Bagga, Winnie Wong, Eric Khoo
INTRODUCTION: To investigate the efficacy and toxicity of radiation therapy (RT) after radical prostatectomy (RP) for prostate cancer at Radiation Oncology Centres, Toowoomba. METHODS: The electronic medical records of 130 consecutive patients with histologically proven prostate adenocarcinoma who underwent post-prostatectomy RT between January 2008 and December 2014 were analysed. Primary endpoint was Biochemical Recurrence (BCR) after RT. BCR was defined by PSA > 0...
August 14, 2017: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/28803358/prospective-head-to-head-comparison-of-11-c-choline-pet-mr-and-11-c-choline-pet-ct-for-restaging-of-biochemical-recurrent-prostate-cancer
#12
Matthias Eiber, Isabel Rauscher, Michael Souvatzoglou, Tobias Maurer, Markus Schwaiger, Konstantin Holzapfel, Ambros J Beer
PURPOSE: Whole-body integrated (11)C-choline PET/MR might provide advantages compared to (11)C-choline PET/CT for restaging of prostate cancer (PC) due to the high soft-tissue contrast and the use of multiparametric MRI, especially for detection of local recurrence and bone metastases. MATERIALS AND METHODS: Ninety-four patients with recurrent PC underwent a single-injection/dual-imaging protocol with contrast-enhanced PET/CT followed by fully diagnostic PET/MR...
August 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28803033/the-risk-of-tumour-recurrence-in-patients-undergoing-renal-transplantation-for-end-stage-renal-disease-after-previous-treatment-for-a-urological-cancer-a-systematic-review
#13
REVIEW
Romain Boissier, Vital Hevia, Harman Max Bruins, Klemens Budde, Arnaldo Figueiredo, Enrique Lledó-García, Jonathon Olsburgh, Heinz Regele, Claire Fraser Taylor, Rhana Hassan Zakri, Cathy Yuhong Yuan, Alberto Breda
CONTEXT: Renal transplantation is the gold standard renal replacement therapy in end-stage renal disease owing to its superior survival and quality of life compared with dialysis. When the potential recipient has a history of cancer, the waiting period before radiotherapy is usually based on the Cincinnati Registry. OBJECTIVE: To systematically review all available evidence on the risk of cancer recurrence in end-stage renal disease patients with a history of urological cancer...
August 9, 2017: European Urology
https://www.readbyqxmd.com/read/28801478/phosphatases-and-solid-tumors-focus-on-glioblastoma-initiation-progression-and-recurrences
#14
REVIEW
Matthias Dedobbeleer, Estelle Willems, Stephen Freeman, Arnaud Lombard, Nicolas Goffart, Bernard Rogister
Phosphatases and cancer have been related for many years now, as these enzymes regulate key cellular functions, including cell survival, migration, differentiation and proliferation. Dysfunctions or mutations affecting these enzymes have been demonstrated to be key factors for oncogenesis. The aim of this review is to shed light on the role of four different phosphatases (PTEN, PP2A, CDC25 and DUSP1) in five different solid tumors (breast cancer, lung cancer, pancreatic cancer, prostate cancer and ovarian cancer), in order to better understand the most frequent and aggressive primary cancer of the central nervous system, glioblastoma...
August 11, 2017: Biochemical Journal
https://www.readbyqxmd.com/read/28799121/3-t-multiparametric-mri-characteristics-of-prostate-cancer-patients-suspicious-for-biochemical-recurrence-after-primary-focal-cryosurgery-hemiablation
#15
Michael Kongnyuy, Daniel M Halpern, Corinne C Liu, Kaitlin E Kosinski, David J Habibian, Anthony T Corcoran, Aaron E Katz
INTRODUCTION: We aimed to report on multiparametric MRI (mpMRI) characteristics of post-primary focal cryosurgery (PFC) patients suspected of biochemical recurrence (BCR) by the Phoenix criteria. METHODS: We retrospectively reviewed all patients at our institution who had undergone PFC. Prostate-specific antigen nadir was determined using 2 or more post-PFC values. Suspicion of BCR was determined using the Phoenix criteria (nadir + 2 ng/ml). At the discretion of the physician, pre-and post-PFC 3-T mpMRIs were obtained and in a few cases biopsies were performed...
August 10, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28798829/does-surgical-delay-for-radical-prostatectomy-affect-patient-pathological-outcome-a-retrospective-analysis-from-a-canadian-cohort
#16
Marc Zanaty, Mansour Alnazari, Kelsey Lawson, Mounsif Azizi, Emad Rajih, Abdullah Alenizi, Pierre-Alain Hueber, Malek Meskawi, Cedric Lebacle, Thierry Lebeau, Serge Benayoun, Pierre I Karakiewicz, Assaad El-Hakim, Kevin C Zorn
INTRODUCTION: We sought to assess the impact of surgical wait time (SWT) to robot-assisted radical prostatectomy (RARP) on final pathological outcome. METHODS: A retrospective review of RARP patient records operated between 2006 and 2015 was conducted. SWT was defined as period from prostate biopsy to surgery. Primary outcome was the impact on postoperative Cancer of the Prostate Risk Assessment (CAPRA-S) score. Patients were stratified according to D'Amico risk categories...
August 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28798822/an-assessment-of-prostate-cancer-research-international-active-surveillance-prias-criteria-for-active-surveillance-of-clinically-low-risk-prostate-cancer-patients
#17
Vitor da Silva, Ilias Cagiannos, Luke T Lavallée, Ranjeeta Mallick, Kelsey Witiuk, Sonya Cnossen, James A Eastham, Dean A Fergusson, Chris Morash, Rodney H Breau
INTRODUCTION: Active surveillance is a strategy to delay or prevent treatment of indolent prostate cancer. The Prostate Cancer Research International: Active Surveillance (PRIAS) criteria were developed to select patients for prostate cancer active surveillance. The objective of this study was to compare pathological findings from PRIAS-eligible and PRIAS-ineligible clinically low-risk prostate cancer patients. METHODS: A D'Amico low-risk cohort of 1512 radical prostatectomy patients treated at The Ottawa Hospital or Memorial Sloan Kettering Cancer Centre between January 1995 and December 2007 was reviewed...
August 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28797587/subcutaneous-adipose-tissue-characteristics-and-the-risk-of-biochemical-recurrence-in-men-with-high-risk-prostate-cancer
#18
Andrew M McDonald, John B Fiveash, Robert S Kirkland, Rex A Cardan, Rojymon Jacob, Robert Y Kim, Michael C Dobelbower, Eddy S Yang
PURPOSE/OBJECTIVE(S): To assess subcutaneous adipose tissue characteristics by computed tomography (CT) as potential imaging biomarkers predictive of biochemical recurrence in men with high-risk prostate cancer receiving radiotherapy (RT). MATERIALS AND METHODS: This retrospective study included men with high-risk prostate cancer (PSA>20ng/ml, Gleason score ≥8, or clinical extraprostatic extension) treated between 2001 and 2012. All patients received definitive, dose-escalated external beam RT along with a course of neoadjuvant, concurrent, and adjuvant androgen deprivation therapy (ADT)...
August 7, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28797228/oncological-outcomes-in-an-australian-cohort-according-to-the-new-prostate-cancer-grading-groupings
#19
K R Beckmann, A D Vincent, M E O'Callaghan, P Cohen, S Chang, M Borg, S M Evans, D M Roder, K L Moretti
BACKGROUND: A new 5-tiered grading grouping system has recently been endorsed for reporting of prostate cancer (PCa) grade to better reflect escalating risk of progression and cancer death. While several validations of the new grade groupings have been undertaken, most have involved centralised pathological review by specialist urological pathologists. METHODS: Participants included 4268 men with non-metastatic PCa diagnosed between 2006 and 2013 from the multi-institutional South Australia Prostate Cancer Clinical Outcomes Collaborative registry...
August 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28795303/the-feasibility-of-prostate-specific-membrane-antigen-positron-emission-tomography-psma-pet-ct-guided-radiotherapy-in-oligometastatic-prostate-cancer-patients
#20
O C Guler, B Engels, C Onal, H Everaert, R Van den Begin, T Gevaert, M de Ridder
BACKGROUND: To investigate the efficacy and toxicity of 68Ga-PSMA-HBED-CC ((68)Ga-PSMA) PET-CT-guided RT in the treatment of oligometastatic prostate cancer retrospectively. METHODS: A total of 23 prostate cancer patients with biochemical relapse, of which 13 were castration sensitive (CS) and 10 castration resistant (CR), were treated with intensity-modulated and image-guided RT (IMRT-IGRT) on ≤3 metastases detected by (68)Ga PSMA PET-CT. Androgen deprivation therapy was continued in CR patients...
August 9, 2017: Clinical & Translational Oncology
keyword
keyword
33996
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"